Immunology and Genetics of Type 1 Diabetes

Michael P. Morran,1 Gilbert S. Omenn2 and Massimo Pietropaolo1

1 Laboratory of Immunogenetics, Brehm Center for Type 1 Diabetes Research and Analysis, Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
2 Center for Computational Medicine and Biology, Departments of Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, MI

ABSTRACT

Type 1 diabetes is one of the most well-characterized autoimmune diseases. Type 1 diabetes compromises an individual’s insulin production through the autoimmune destruction of pancreatic β-cells. Although much is understood about the mechanisms of this disease, multiple potential contributing factors are thought to play distinct parts in triggering type 1 diabetes. The immunological diagnosis of type 1 diabetes relies primarily on the detection of autoantibodies against islet antigens in the serum of type 1 diabetes mellitus patients. Genetic analyses of type 1 diabetes have linked human leukocyte antigen, specifically class II alleles, to susceptibility to disease onset. Environmental catalysts include various possible factors, such as viral infections, although the evidence linking infections with type 1 diabetes remains inconclusive. Imbalances within the immune system’s system of checks and balances may promote immune activation, while undermining immune regulation. A lack of proper regulation and overactive pathogenic responses provide a framework for the development of autoimmune abnormalities. Type 1 diabetes is a predictable and potentially treatable disease that still requires much research to fully understand and pinpoint the exact triggering events leading to autoimmune activation. In silico research can aid the comprehension of the etiology of complex disease pathways, including Type 1 diabetes, in order to and help predict the outcome of therapeutic strategies aimed at preserving β-cell function. Mt Sinai J Med 75:314–327, 2008. © 2008 Mount Sinai School of Medicine

Key Words: adaptive immunity, autoimmunity, genetics in type 1 diabetes, innate immunity, type 1 diabetes.

IMMUNE SYSTEM REVIEW

The immune system is the body’s natural defense system against invading pathogens. It protects the body from infection and works to communicate an individual’s well-being through a complex network of interconnected cells and cytokines. This system has the power to initiate a wide gamut of cellular responses with the ability to directly attack an invading organism or signal cells to begin the healing process. Although this system is an associated host defense, an uncontrolled immune system has the potential to trigger negative complications in the host. Therefore, well-controlled regulation of the immune system is necessary in order to prevent autoimmune responses from occurring.

In order to protect the body against foreign pathogens, the immune system has developed throughout evolution to recognize the difference between the self and nonself. The ability to become self-tolerant toward the body’s own proteins and antigens is critical to maintaining a properly functioning immune system. An immune system that loses tolerance to the self loses the ability to differentiate between friend and foe in immunological battles. Loss of tolerance leads the immune system toward autoimmune responses, in which the body attacks itself, causing substantial damage to the self, even inflicting irreversible damage.

The immune system is composed of 2 unique branches, each with its own responsibilities. The
T1D Development

Fig 1. T1D development. A discrete balancing act is performed by the immune system in order to attack foreign pathogens while protecting against the promotion of autoimmunity. Multiple contributing factors influence the development of T1D, including genetics, the environment, and cellular signals. In a normal individual the immune system is balanced, possessing the ability to both promote and suppress cellular responses to pathogens. When an immune system is unbalanced and favors inflammation or excessive cellular responses, the system is unbalanced and favors excessive regulation of cellular responses, the system is protected against the development of T1D and autoimmunity. Abbreviations: T1D, type 1 diabetes. Adapted from Annual Review of Immunology.102 [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com].

innate immune system is the body’s first line of defense against invading pathogens. This system recognizes common structural components of pathogens and elicits immune responses to signal the presence of pathogens and infection.1 The adaptive immune system is the body’s secondary line of defense and specifically targets identified pathogens. This system is antigen-specific and generates immunological memory within the host, which allows for more efficient pathogen clearance upon repeat exposure to the same pathogen.1 Although these 2 systems are termed different branches of the immune system, they must work together as one unified system to protect the body. The 2 branches of the immune system rely on each other to help properly perform their jobs. If either branch fails to perform its job, the other branch suffers. Regulatory malfunctions in either system can ultimately lead to the generation of unwarranted or unregulated autoimmune responses. Underlying an immune response lies a delicate network of cell types and cytokines that communicate to begin, generate, and end an immune response. If an immune system becomes unbalanced, this delicate network, responsible for preventing autoimmunity, promotes it (Figure 1).

The immune system protects the host, but it also possesses the power to harm the host as well. Numerous autoimmune diseases have been characterized over time. This article provides an overview of how alterations in the immune system, due to genetics, cellular malfunctions, or cell signaling issues, lead to the development and pathogenesis of autoimmune diseases, specifically type 1 diabetes (T1D). Understanding mechanistically how T1D and autoimmune responses are triggered is essential in order to develop strategies to combat these diseases.

TYPE 1 DIABETES OVERVIEW

Diabetes mellitus is a group of diseases characterized by the body’s inability to accurately maintain normal blood glucose levels, leading to multiple detrimental effects. Insulin is an important hormone in glucose metabolism. When released, it signals cells to take up glucose. If the body is unable to produce insulin, blood glucose levels remain elevated, and this is termed hyperglycemia. T1D is an autoimmune disease in which the immune system targets and destroys the insulin-producing β-cells found in the islets of Langerhans in the pancreas. Without insulin, individuals develop the clinical syndrome of T1D.

T1D is characterized by autoantibody production and progressive infiltration of immune cells into
the islets of the pancreas, followed by the destruction of the islet cells. During the onset of T1D, cells from both the innate and adaptive immune systems infiltrate islet lesions to produce insulitis. Studies using human and murine models of diabetes have demonstrated that the autoimmune destructive process in T1D occurs in a cell-mediated organ-specific manner and requires both CD4+ and CD8+ T cells as well as macrophages. These cells accumulate in an islet lesion but are nondestructive. An unknown triggering event occurs, which promotes the autoimmune destruction of the β-cells. Clinical manifestations of diabetes occur after 90% of an individual’s β-cell mass is destroyed.

The exact trigger for the onset of T1D is still unknown, as discussed later, although the mechanism by which the insulin-producing β-cells are destroyed is well understood. The destructive process is T cell–mediated. Once the islets have become infiltrated and highly populated with T cells and macrophages, a subsequent triggering event occurs to activate these cells. T cells, B cells, and macrophages communicate via antigen presentation and can, in turn, activate each other via cytokines and direct cell communication through surface receptors. With such a high population of immune cells centered in one distinct area, activation signals can travel fast, initiating a destructive cascade easily.

In general, macrophages play the role of antigen-presenting cells (APCs), and so they can directly pick up and present β-cell antigens. This leads to the activation of β-cell–cytotoxic CD8+ T cells and the generation of autoreactive CD4+ effector T cells. Cytotoxic T cells can directly kill β-cells, whereas effector T cells can initiate the activation of B cells, thus prompting autoantibody production. Once the immune system is triggered or activated, it begins to process and present self antigens to T cells, generating the autoimmune process that leads progressively to the clinical manifestations of T1D.

T cells possess the ability to directly destroy β-cells in a cytotoxic manner but also hold the power to directly influence the induction of β-cell destruction through the release of cytotoxic molecules, including cytokines, granzyme B, and perforin. T cells can also signal β-cell death through the Fas pathway. β-Cell apoptosis is promoted by activation of the caspase pathway through multiple mechanistic pathways, including Fas and Fas ligand interactions, nitric oxide and oxygen-derived free radicals, and membrane disruption due to perforin or granzyme B. Cytokine production by activated T cells may be a key factor in β-cell death, influential cytokines released by T cells include: interleukin 1 (IL-1), interferon γ (IFNγ), and tumor necrosis factor α (TNFα), all of which up-regulate Fas and the production of Fas ligand, nitric oxide, and free-radicals. Other notable cytokines are IL-2, IL-12, IL-17, and IL-18, all of which seem to promote an inflammatory state biased to T helper 1 type responses.

AUTOANTIGENS IN TYPE 1 DIABETES

During the progression of T1D, multiple autoimmune processes occur. Human and murine studies of T1D have illustrated that, as the severity of disease increases, so does the number of autoantigens and autoantibodies. Over the course of development, β-cells go through multiple divisions and changes in cell volume and increase in cell mass. During this time, β-cells grow, develop, and eventually die; these dead cells may be engulfed and processed by APCs. In an insulitis lesion, these APCs presenting processed β-cell components have the potential to trigger the generation of β-cell autoreactive T cells.

Most well-known autoantigens are associated with β-cell components, including insulin, glutamic acid decarboxylase (GAD), and islet-cell antigen-2 (IA-2). Insulin is the first antigenic target detectable during the early progression of diabetes, although most autoantibodies are targeted against the β-cells themselves and other β-cell–secreted proteins. Recently, ZnT-8, a pancreatic β-cell–specific zinc transporter, has been identified as a candidate autoantigen. Although research is limited on this molecule, strong evidence already supports the association of ZnT-8 autoantibodies with T1D. During the progression of T1D, a process of autoantigen epitope spreading occurs. Epitope spreading provides an explanation of how the immune system is capable of recognizing increasing numbers of autoantigens in correlation with increased T1D disease severity. Epitope spreading begins with the immune system recognizing and mounting an immune response against a single antigen, which is recognized via a single epitope. Over time, new antigens can be recognized, and previously recognized antigens can be differentially processed by APCs to generate multiple epitopes for a single antigen.

One can think of this process as similar to a tree growing toward autoimmunity. In Figure 2, the tree stem symbolizes an immune system at birth that lacks autoimmunity. As this tree grows...
Fig 2. Autoantigen epitope spreading in T1D. As the severity of symptoms associated with T1D increases over time, so does the number of autoantigens recognized by the immune system. Epitope spreading begins once the immune system is triggered within the pancreas, leading to the processing and presentation of self antigens. As β-cell destruction takes place, multiple self antigens become targets of the immune system. During this process, insulin is the first antigenic target, and it is followed by other β-cell–associated components, such as GAD65 and IA-2. Over time, autoantigens are processed differently, creating various recognition epitopes for a given antigen. In Figure 1, the tree symbolizes an immune system at birth that lacks autoimmunity. As the tree grows toward autoimmune T1D, its limbs represent targeted self antigens that develop. As T1D progresses, multiple limbs grow off the tree, each from a different antigen. These growing limbs next branch off, representing the unique epitopes recognized from differential processing of similar self peptides. As T1D develops, the tree grows toward autoimmunity by increasing both the number of limbs and the number of branches on a given limb, representing the process of epitope spreading observed in T1D disease development.

Abbreviations: GAD65, glutamic acid decarboxylase 65; IA-2, islet-cell antigen-2; T1D, type 1 diabetes.

toward autoimmune T1D, its limbs represent developing targeted self antigens. Next, multiple limbs grow from the stem, each targeting different antigens. These growing limbs branch off, representing the unique epitopes recognized from differential processing of similar peptides. It has been shown that autoantibody production has been detected up to 5 years prior to the development of hyperglycemic events, and this indicates that autoantibody production precedes the clinical manifestation of T1D. As T1D develops, the tree grows toward autoimmunity by increasing both the number of limbs (targeted antigens) and the number of branches on a given limb (recognized epitopes for a particular antigen). Although the progression and mechanisms behind the development of T1D are understood in general terms, many questions remain to be answered concerning how the autoimmune disease state becomes triggered toward autoreactivity.

We have provided evidence suggesting that a subset of cytoplasmic islet-cell antibodies (ICAs) is related to a more rapid progression to insulin-requiring diabetes in glutamic acid decarboxylase 65 (GAD65) and IA-2 antibody–positive relatives of proband patients versus relatives with GAD65 and IA-2 antibodies without ICAs (Figure 3). The precise nature of the antigen(s) detected by the indirect immunofluorescence ICA assay remains enigmatic, but its utility to predict future development of diabetes mellitus in individuals with other circulating ICAs has recently been confirmed.

WHAT ARE THE GENES ASSOCIATED WITH TYPE 1 DIABETES?

Although it has been suggested that multiple genes play a role in disease susceptibility, there is strong evidence for only 2 chromosomal regions that are associated with T1D: the human leukocyte antigen (HLA) region on chromosome 6p21 [insulin-dependent diabetes mellitus 1 (IDDM1)] and the insulin gene region on chromosome 11p15 [insulin-dependent diabetes mellitus 2 (IDDM2)]. The contributions of these 2 loci to familial inheritance are approximately 42% for IDDM1 and 10% for IDDM2. As a result of genome-wide searches, many other putative loci have been proposed to be related to T1D. These loci along with some potential candidate genes are listed in Tables 1 and 2. The fact that in humans the highest risk-conferring locus linked to the disease is the HLA cluster and, in particular, HLA genes encoding specific class II alleles strongly indicates an important role of the immune cells in both the development and activation of the autoimmune response leading to disease onset.
Interestingly, the same HLA locus seems to have the corresponding susceptibility influence in the primary mouse model of T1D, the nonobese diabetic (NOD) mouse (Table 3).27 The immune-mediated processes of β-cell destruction are mainly T cell–dependent and chronic in both mouse and rat models of T1D, and this makes it more likely to be the same in humans.27 Comparative mapping of human (IDDM) and NOD mouse insulin-dependent diabetes (Idd) genes are shown in Table 3.

Genetic factors have long been thought to be linked to the development of T1D. Although it has been hypothesized that in monozygotic twins a discordance rate greater than 50% could be explained by environmental factors of disease development, studies using both monozygotic and dizygotic twins have suggested that environmental factors have few causative roles in the development of islet autoimmunity, whereas genetic similarities in dizygotic twins seem more important in determining susceptibility to diabetes.28 T1D is a polygenic disease29 in which there presumably exist a small number of genes with large effects, HLA being the main example, and a large number of genes with small effects overall.30

THE HUMAN LEUKOCYTE ANTIGEN COMPLEX

The short arm of human chromosome 6 (6p21) accommodates a ~3.5-megabase genetic segment containing a group of immune response genes.
Table 1. Effect of Human Leukocyte Antigen Alleles on Type 1 Diabetes Susceptibility.

<table>
<thead>
<tr>
<th>DQ Alleles</th>
<th>Effect</th>
<th>Associated DR</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1* 0302, A1* 0301</td>
<td>Susceptible</td>
<td>DR4</td>
</tr>
<tr>
<td>B1* 0201, A1* 0501</td>
<td>Susceptible</td>
<td>DR3</td>
</tr>
<tr>
<td>B1* 0501, A1* 0101</td>
<td>Susceptible</td>
<td>DR1</td>
</tr>
<tr>
<td>B1* 0201, A1* 0301</td>
<td>Susceptible (African Americans)</td>
<td>DR7</td>
</tr>
<tr>
<td>B1* 0502, A1* 0102</td>
<td>Susceptible (Sardinia)</td>
<td>DR2 (DR16)</td>
</tr>
<tr>
<td>B1* 0303, A1* 0301</td>
<td>Susceptible (Japanese)</td>
<td>DR9</td>
</tr>
<tr>
<td>B1* 0602, A1* 0102</td>
<td>Protective</td>
<td>DR2 (DR15)</td>
</tr>
<tr>
<td>B1* 0301, A1* 0501</td>
<td>Protective</td>
<td>DR5</td>
</tr>
<tr>
<td>B1* 0201, A1* 0201</td>
<td>Neutral</td>
<td>DR7</td>
</tr>
<tr>
<td>B1* 0303, A1* 0301</td>
<td>Neutral</td>
<td>DR4</td>
</tr>
<tr>
<td>B1* 0301, A1* 0301</td>
<td>Neutral</td>
<td>DR4</td>
</tr>
</tbody>
</table>

Table 2. Genetic Risk Estimates for Human Leukocyte Antigen Class II in T1D.

<table>
<thead>
<tr>
<th>High-Risk Genotype</th>
<th>Risk in an Individual with This Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>DQB1* 0302 (DQ3.2)</td>
<td>1 in 60</td>
</tr>
<tr>
<td>DQ3.2/DQ2 (DR3)</td>
<td>1 in 25</td>
</tr>
<tr>
<td>DQB1* 0302 and a family history of IDDM</td>
<td>1 in 10</td>
</tr>
<tr>
<td>DQ3.2/DQ2 (DR3) and a family history of T1D</td>
<td>1 in 4</td>
</tr>
</tbody>
</table>

NOTE: This table was adapted from Annual Review of Medicine.26

Abbreviations: IDDM, insulin-dependent diabetes mellitus; T1D, type 1 diabetes.

The genes that encode class I MHC are located at the HLA-A, HLA-B, and HLA-C loci, whereas class II molecules are encoded by the DR, DQ, and DP genes. Other genes in this cluster include transporters associated with antigen processing and low-molecular-weight proteins, both of which are involved in antigen processing. A third region of the MHC, termed class III, encodes several molecules having a variety of functions, such as complement...
components (C4A, C4B, factor B, and C2), tumor necrosis factor α and tumor necrosis factor β, and the 21-hydroxylase genes (CYP21P and CYP21).

Polymerase chain reaction studies have provided researchers with a rapid means of estimating T1D susceptibility in comparison with serological techniques. Polymerase chain reaction amplification of individuals’ HLA alleles in a variety of racial and ethnic groups has revealed that there is a specific human DQβ chain variant encoding a neutral amino acid (alanine, valine, or serine), rather than aspartic acid at position 57 (non-Asp-57), is strongly associated with T1D. In contrast, negatively charged aspartic acid at position 57 (non-Asp-57) appears to confer resistance to T1D progression. This association is much stronger than the association of transcription of these genes may influence the amount of antigen binding. An increased level of antigen binding depends on the conformation of the antigen-binding site and consequently to a modification of the affinity of the class II molecule for the diabetogenic peptide(s). As support for this hypothesis, it is known that Asp-57 is involved in hydrogen and salt bonding with both the peptide main chain and the DRA Arg-76 side chain. Theoretically, modifications in the DRA Arg-76 residue would also alter the antigen-binding site. It is noteworthy that studies of the regulatory regions of the genes encoding DQ α and DQ β chains have shown that the level of transcription of these genes may influence the amount of antigen binding. An increased level of production of a class II chain may increase the availability for dimerization. Studies by Demotz et al. have suggested that relatively few class II individuals at high risk of developing the disease with no detectable signs of islet autoimmunity, who could then be enrolled in intervention trials aimed at preventing overt disease.

The mechanisms by which the class II genes can influence susceptibility to or protection from T1D are still the subject of discussion. Brown et al. characterized the structure of the crystallized HLA class II molecule. One hypothesis is that effective antigen binding depends on the conformation of the antigen-binding site on the DQ dimer. The 2 critical residues, DQα Arg-52 and DQβ Asp-57, are located at opposite ends of the α-helices that form the antigen-binding site of the DQ molecule. It has been postulated that a substitution of an amino acid residue at these positions of the DQ molecule leads to conformational changes of the antigen-binding site and consequently to a modification of the affinity of the class II molecule for the diabetogenic peptide(s). As support for this hypothesis, it is known that Asp-57 is involved in hydrogen and salt bonding with both the peptide main chain and the DRA Arg-76 side chain. Theoretically, modifications in the DRA Arg-76 residue would also alter the antigen-binding site. It is noteworthy that studies of the regulatory regions of the genes encoding DQ α and DQ β chains have shown that the level of transcription of these genes may influence the amount of antigen binding. An increased level of production of a class II chain may increase the availability for dimerization. Studies by Demotz et al. have suggested that relatively few class II individuals at high risk of developing the disease with no detectable signs of islet autoimmunity, who could then be enrolled in intervention trials aimed at preventing overt disease.

The mechanisms by which the class II genes can influence susceptibility to or protection from T1D are still the subject of discussion. Brown et al. characterized the structure of the crystallized HLA class II molecule. One hypothesis is that effective antigen binding depends on the conformation of the antigen-binding site on the DQ dimer. The 2 critical residues, DQα Arg-52 and DQβ Asp-57, are located at opposite ends of the α-helices that form the antigen-binding site of the DQ molecule. It has been postulated that a substitution of an amino acid residue at these positions of the DQ molecule leads to conformational changes of the antigen-binding site and consequently to a modification of the affinity of the class II molecule for the diabetogenic peptide(s). As support for this hypothesis, it is known that Asp-57 is involved in hydrogen and salt bonding with both the peptide main chain and the DRA Arg-76 side chain. Theoretically, modifications in the DRA Arg-76 residue would also alter the antigen-binding site. It is noteworthy that studies of the regulatory regions of the genes encoding DQ α and DQ β chains have shown that the level of transcription of these genes may influence the amount of antigen binding. An increased level of production of a class II chain may increase the availability for dimerization. Studies by Demotz et al. have suggested that relatively few class II
heterodimers need to be present on the surface of an APC to efficiently crosslink the T cell receptor (TCR) and initiate a T cell response.

ENVIRONMENTAL FACTORS INFLUENCING TYPE 1 DIABETES

Although T1D has long been considered to be directly linked to genetic factors, researchers have been searching for environmental factors capable of triggering T1D progression. Epidemiologists have examined trends for environmental triggers through major geographical variations in T1D incidence, temporal trends in the incidence of T1D, and migration studies. The responsibility of environmental factors for T1D is strongly supported by statistical evidence showing that the incidence of newly diagnosed T1D subjects with high-risk HLA genotypes has decreased over the last decades, whereas newly diagnosed T1D with low-risk or even protective HLA genotypes has increased. Specific environmental factors that have been investigated include dietary compounds, including cow’s milk, wheat gluten, soy products, fats, and even coffee or tea, along with vitamin deficiencies, N-nitroso compounds and other toxins, and viral infections. One specific hypothesis associates the development of T1D in Finland with seasonal changes in climate, it being more common during the cold season. Although the genetic argument has long been considered the main factor in triggering T1D, new studies are pointing to the importance of the environment.

VIRAL TRIGGERS OF TYPE 1 DIABETES

Although multiple environmental factors have been implicated as possible triggers of T1D, viral disease induction has long been argued as one of the main potential environmental triggers. Viruses in general have been receiving much attention as possible triggers in T1D because of their ability to mechanistically generate an active immune response when encountered in the host. In the case of T1D, the host environment is primed with immune cells poised to activate; all they need is an immunological stimulus. Researchers in the aforementioned seasonal pattern study on T1D induction even argue that the primary culprit responsible for triggering induction of disease during the winter season may actually be viral infections. Several viruses have been directly implicated as potential triggers of T1D, including enterovirus, adenovirus, Coxsackie B virus, cytomegalovirus, hepatitis C virus, mumps virus, rotavirus, and rubella virus. The presence of a viral infection can lead to immune cell activation through various possible mechanisms. Viruses may directly alter a host cell or tissue in such a manner that the immune system identifies it as an immunological target. Targeted host cells are lysed, releasing self peptides and fragments of the host cell into the circulation, where they may be processed and presented via APCs. Viruses can directly alter the immune system of the host by inducing polyclonal B cell activation, the release of lymphokines, the activation of immune cells, and the disruption of the strict immune balance between T helper 1 and T helper 2 type responses, thus promoting unwarranted immune activation. It has been hypothesized that antiviral antibodies also can lead to the formation of anti-idiotypic antibodies, which can become autoreactive if the first antibody is generated against the part of the virus that interacts with the host.

Molecular mimicry is by far one of the most well studied processes associated with viral triggering mechanisms and T1D disease induction. Viruses produce proteins similar to those of the host. Although not all viral proteins share homology with the host, certain viral components share a distinct homology with identified β-cell antigens targeted in an autoimmune response. Upon reacting to a viral infection, the immune system may process and present a homologous viral protein in such a manner that the epitope targeted by the immune system can interact with both self and viral proteins. This process becomes especially important with respect to T1D disease induction if the homologous viral protein that is recognized and processed shares a distinct homology with β-cell–associated proteins. Unintentional activation of an immune response geared toward β-cell–associated proteins put together with epitope spreading of antigens is a volatile combination for the host.

GAD is a well-defined example of an autoantigen in T1D that shares homology with viral proteins. Researchers have demonstrated that GAD peptides share mimicry with the P2-C viral sequence of the Coxsackie B virus and the major outer capsid protein of rotavirus. Immunization studies of mice using homologous Coxsackie viral sequences have induced T cell immune responses that cross-react with GAD peptides, showing that viral homology may induce responses to self proteins. Furthermore, researchers have linked rotavirus infection and pancreatic islet autoimmunity in children on the HLA-DR4 background, linking both viral induction and genetic susceptibility. Researching molecular
mimicry and viral induction of T1D provides a pivotal bridge between an environmental factor and an immunological system responsible for T1D. Whether T1D is triggered environmentally, genetically, or in combination, it is still not known how exactly to prevent disease progression once it starts. Several other unknown immunological factors may play a role in triggering T1D.

**INNATE IMMUNE SYSTEM**

The innate immune system is the body's first line of defense against invading microbes and pathogens. Although this system does not generate long-term antigen-specific immunological memory, this system does have a high degree of immunological specificity when encountering potential pathogens. The innate immune system is composed of macrophages, dendritic cells, natural killer cells, neutrophils, and epithelial cells, all of which have their own unique role in the framework of an innate response. The role of the innate immune system is to survey and detect pathogens via host cell receptors that are able to recognize common structural elements expressed by pathogens. These pattern recognition receptors (PRRs), though specific, are not clonal and lack the ability for clonal expansion of cells, as seen in the adaptive immune system. TLRs are not the only PRRs used by cells of the innate immune system. Non-TLR PRRs include Nod-like Receptors (NLRs), Triggering Receptors Expressed on Myeloid Cells (TREMs), and C-type Lectin Receptors (CLRs) have not been directly linked to autoimmunity or T1D, but represent a new class of receptors that may be responsible for triggering autoimmune responses or autoimmune initiation of the adaptive immune system. Any immunological trigger directed against self is potentially dangerous. Innate immune cells triggered via self ligand binding to TLRs or non-TLR PRRs could in turn activate T cells and an adaptive immune response because of the production of cytokines and other inflammatory signals. Once the balance of the immune system is flipped toward autoreactivity, negative outcomes are sure to follow.

The innate immune system has been well studied in the context of T1D development in both humans and the NOD mouse. T1D disease progression has been characterized in the 2 phase processes of asymptomatic inflammation of the islets followed by autoimmune destruction of the islets. During phase 1, macrophages infiltrate the pancreatic islets and may be responsible for the asymptomatic inflammation that takes place there. Once activated, macrophages can secrete nitrogen and oxygen free radicals, as well as inflammatory cytokines, into their surrounding microenvironment. These molecules can either directly damage surrounding cells or initiate cellular damage by in turn activating other cell types to cause damage. It has even been illustrated that without the presence of macrophages in NOD mice, differentiation of β-cell–cytotoxic T cells does not take place. Restoring macrophages in these types of deletion experiments restores the ability of β-cell–cytotoxic T cell generation, thus illustrating the importance of macrophages in T1D disease progression. The innate and adaptive immune systems communicate using an intricate system of checks and balances. Once one end of the system becomes disrupted, the whole system can falter.

**ADAPTIVE IMMUNE SYSTEM**

The adaptive immune system is the body's second line of defense against pathogens and disease,
activated by the innate immune system. This system is antigen-specific, facilitating the generation of immunological memory, which serves to eliminate reoccurring pathogens more effectively upon repeat exposure to a given pathogen. This highly specific system uses receptor interaction between T cells and APCs to determine self from nonself. The hallmarks of an adaptive immune response are the generation of long-term immunological memory, peptide presentation in the context of MHCs, and the production of antigen-specific antibodies.78

T lymphocytes and their specific TCRs are a crucial part of the adaptive immune system. T lymphocytes are generated in the thymus, each having its own structurally diverse and unique antigen-recognizing receptor known as the TCR. The TCR recognizes processed antigenic peptides presented in the context of MHC via APCs. Once recognition of a peptide-bound MHC complex occurs via the TCR, a cascade of signaling events takes place, leading to either a CD4+ T cell or CD8+ T cell response, depending on which class of MHC, either MHC class I or MHC class II, was initially recognized by the TCR. Ultimately, once a TCR recognizes a processed peptide in the context of an MHC, immunological events take place that bring about either the direct targeted destruction of cells presenting the peptide or the generation of an antibody response and further T cell activation.

In phase 2 of T1D disease progression, both T and B lymphocytes accumulate in an islet lesion, where they can be activated against self antigens to trigger an immunological response toward the self. This autoreactive immune response then leads to the destruction of the insulin-producing β-cell within the pancreas. Both MHC class I and MHC class II restricted T cells are necessary for T1D disease progression in both humans and NOD mice.79,80 Anti-insulin CD4+ T cell populations have been reported in NOD mice. It is thought that interactions between insulin peptides and MHC molecules can cause the development of an autoimmune T cell repertoire.81 Although this process is not totally understood, it is necessary to determine what exact factors are causing the immune system to become unregulated in such a manner as to promote an autoimmune response.

REGULATION VIA T CELLS

Keeping the immune system tolerant is a strict balancing act: excessive regulation restricts proper immune function, whereas a lack of regulation permits overt immune function with the potential to target the self. Regulating when an immune response begins, continues, and ends is a very important part of the immune system’s checks and balances. Regulatory T cells (T regs) and natural killer T (NKT) cells are 2 subtypes of T cells that are important regulators in the progression of T1D and autoimmune diseases.

T regs are a unique population of T cells that express the forkhead transcription factor forkhead box P3 (FOXP3) and are CD+4 CD+4-25.91–93 T regs are well-known immunoregulators that can suppress proliferation of effector cells by shutting down IL-2 activation pathways.95 T regs help the immune system maintain proper T cell homeostasis by preventing T cell activation, and this in turn leads to the development of inflammatory responses.96,97 T regs work to shut off an active T cell response and are thought to prevent autoimmune development by regulating the expansion of T cell populations, T cell differentiation, and effector T cell function.98 Although individuals with T1D have numbers of T regs equal to those of normal healthy individuals,98–91 T regs from T1D individuals display decreased suppressive characteristics, which suggest a defect in T reg function in people suffering from T1D.99,100 Adoptive transfer experiments using T regs in NOD mice have effectively been demonstrated to protect against the onset and progression of T1D.101 Although current use of T regs in NOD mice shows promising therapeutic qualities, the potential use of T regs in humans is not sufficiently understood.

NKT cells share similar characteristics with both natural killer cells and T cells. These cells can cause direct cell lysis due to Fas-ligand interactions and induce cytotoxic damage of cells due to IFNg, like Natural Killer cells102–104, but they are also similar to T cells in that they are biased toward TCR usage and produce IL-4.102–104 When activated, NKT cells produce IL-4, which inhibits inflammatory T helper 1 type responses and promotes inhibitory T helper 2 type responses.96,97 Individuals suffering from T1D show a decreased number of NKT cells along with a decreased ability to produce and secrete IL-4.98 As seen with T regs, adoptive transfer experiments with NKT cells effectively protect against the onset and progression of T1D in NOD mice.99 Because of these 2 types of T cells, individuals that cannot inhibit or properly regulate T cell responses face increased autoimmune problems.

CONCLUDING REMARKS

T1D results from autoimmune destruction/dysfunc-
tion of insulin-secreting cells. Under physiologic
conditions, there is balance between pathogenic T cells that mediate disease such as T cells with marked conservation of their TCRs (eg, insulin) and regulatory cells that control autoimmunity. In T1D and other autoimmune disorders, there is an altered balance between pathogenic and T regs.

Autoantibodies are some of the most potent risk determinants for autoimmune diseases, with relative risk exceeding 100 when all 4 autoantibodies are present in an asymptomatic child. The archetypical model for the application of autoantibodies is T1D. Seminal studies have suggested that using a combination of humoral immunological markers gives a higher predictive value for T1D progression and greater sensitivity without a significant loss of specificity. There is a growing effort as well as a large opportunity for exploring novel strategies alone or in combination with immunomodulation with the ultimate goal of finding the cure for T1D.

Emerging evidence indicates that in silico research is complementary to current experimental approaches in T1D research and has the potential not only to assist researchers in designing laboratory experimentation but also to build a framework of data collection to predict the outcome of therapeutic strategies aimed at halting the β-cell–specific autoimmune process. With support from the Juvenile Diabetes Research Foundation, the Institute for Systems Biology has generated a T1D database (T1Dbase) with numerous data sets of molecular signatures of T1D (http://t1dbase.org/cgi-bin/dispatcher.cgi/welcome/display). Molecular signatures have revealed remarkable differentiation of organ-specific complications as reflected in the work of the Kretzler laboratory on transcription factor binding site patterns in nephropathy associated with T2DM versus nephropathy due to lupus erythematosus, glomerulonephritis, or other causes. Similar studies on T1D-associated nephropathy, are being completed by our group at the National Center for Integrative Biomedical Informatics (https://portal.ncibi.org/portal). Mathematical modeling of the imbalance of T cell subsets in T1D, in work led by Patrick Nelson, is expected to inform our future work.

ACKNOWLEDGMENT

This work was supported by the National Institutes of Health (grants RO1 DK53456, DK56200, and NIDDK PA-04–081 to M.P.) and by the University of Michigan Center for Computational Medicine and Biology Pilot Research Program. The authors gratefully thank the Brehm Coalition for its support. Any research involving human subjects was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the institutional review board; all subjects provided informed consent.

DISCLOSURES

Potential conflict of interest: Nothing to report.

REFERENCES


DOI:10.1002/MSJ


DOI:10.1002/MSJ